They are “actively preparing” for the vaccine launch.
Coronavirus vaccine maker Moderna Inc. received an additional $472 million from the U.S. Biomedical Advanced Research and Development Authority to support development of its coronavirus vaccine. Now the biotech firm says it expects to have about 20 million doses of the vaccine ready to ship in the U.S. by the end of the year.
“From a distribution standpoint, we’re ready,” Dr. Tal Zaks, the company’s chief medical officer, said Thursday. “We expect mRNA-1273 [the name given the vaccine] to be distributed within existing infrastructure. There’s nothing new required that hasn’t already been used for years with many other vaccines.”
Moderna said it is “actively preparing” for the launch of the vaccine, which is one of four going through Phase 3 clinical trials. The company has enrolled 30,000 people in the study and said it should have enough data to seek emergency approval for the shot by the end of November.
As the Lord Leads, Pray with Us…
- For the scientists and researchers at Moderna and other laboratories across the U.S. as they conclude their studies on the effectiveness of a coronavirus vaccine.
- For the earliest doses of the vaccine to be administered to the most vulnerable populations as well as to first responders and healthcare workers.
- For the Food and Drug Administration as they analyze the safety and effectiveness of vaccines for approval.
Sources: Fox Business News, CNBC
